Latest news from HIV Vaccine Trials Network on Newswise en-us Copyright 2024 Newswise 115 31 / /images/newswise-logo-rss.gif /articles/phase-3-mosaic-based-investigational-hiv-vaccine-study-discontinued-following-disappointing-results-of-planned-data-review/?sc=rsin /articles/phase-3-mosaic-based-investigational-hiv-vaccine-study-discontinued-following-disappointing-results-of-planned-data-review/?sc=rsin Wed, 18 Jan 2023 10:00:31 EST A Phase 3 study of an investigational HIV vaccine regimen has been discontinued following a planned, interim review by the study's independent Data and Safety Monitoring Board. The investigational vaccine was generally safe and well tolerated; however, it was not effective at preventing the acquisition of HIV-1. The results of the uniquely designed and implemented Mosaico study underscore the challenges that have faced the global scientific community in the 40-year search for an HIV vaccine, and may provide important data in the ongoing fight against HIV. HIV Vaccine Trials Network /articles/the-nihdaids-cross-network-actghvtnimpaact-tb-vaccine-working-group-calls-for-people-living-with-hiv-to-be-included-in-tuberculosis-vaccine-development/?sc=rsin /articles/the-nihdaids-cross-network-actghvtnimpaact-tb-vaccine-working-group-calls-for-people-living-with-hiv-to-be-included-in-tuberculosis-vaccine-development/?sc=rsin Tue, 11 Oct 2022 18:30:33 EST People living with HIV must be included in clinical trials for new tuberculosis vaccine candidates currently in the development pipeline, say experts on an international panel convened last year to address gaps in the current TB vaccine landscape. Their recommendations appear in a new paper published today in The Lancet HIV. HIV Vaccine Trials Network /articles/additional-antibody-mediated-prevention-amp-trials-data-published-in-nature-medicine/?sc=rsin /articles/additional-antibody-mediated-prevention-amp-trials-data-published-in-nature-medicine/?sc=rsin Mon, 22 Aug 2022 11:00:00 EST An embargoed study published in the Aug. 22, 2022 issue of Nature Medicine identifies a new biomarker that appears effective as a surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1, the most common type of the virus that causes AIDS. Broadly neutralizing antibodies (bnAbs) are defined by their ability to neutralize multiple genetically distinct viral strains. HIV Vaccine Trials Network /articles/hvtn-at-the-24th-international-aids-conference-in-montreal/?sc=rsin /articles/hvtn-at-the-24th-international-aids-conference-in-montreal/?sc=rsin Thu, 28 Jul 2022 10:00:00 EST Scientists, doctors and other health professionals from the HIV Vaccine Trials Network (HVTN) will present research findings and other HIV-related news at AIDS 2022, the International AIDS Conference taking place virtually and in person in Montreal, Canada, July 29 to Aug. 2. HIV Vaccine Trials Network /articles/after-sprint-for-covid-19-vaccines-hvtn-researchers-return-to-hiv-marathon-with-fresh-determination-and-knowledge-launch-clinical-research-registry-and-ad-campaign/?sc=rsin /articles/after-sprint-for-covid-19-vaccines-hvtn-researchers-return-to-hiv-marathon-with-fresh-determination-and-knowledge-launch-clinical-research-registry-and-ad-campaign/?sc=rsin Wed, 18 May 2022 09:55:48 EST SEATTLE (May 18, 2022) - Building on momentum from the highly successful COVID-19 vaccine clinical trials, the HIV Vaccine Trials Network (HVTN) is launching a new HIV awareness campaign and unveiling a first-of-its-kind national registry that will provide updated HIV information and make it easier to learn about and participate in HIV clinical trials at HelpEndHIV.org. HIV Vaccine Trials Network /articles/increased-support-needed-for-a-coordinated-global-hiv-and-covid-19-response/?sc=rsin /articles/increased-support-needed-for-a-coordinated-global-hiv-and-covid-19-response/?sc=rsin Tue, 15 Mar 2022 19:05:12 EST In a JAMA perspective piece, leading infectious disease researchers call for a coordinated response to HIV and COVID-19 globally, building on the successes of key donor programs such as the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program and Global Fund to Fight AIDS, TB and Malaria (GFATM). HIV Vaccine Trials Network /articles/trial-of-innovative-hiv-vaccine-using-mrna-technology-enrolls-first-participant/?sc=rsin /articles/trial-of-innovative-hiv-vaccine-using-mrna-technology-enrolls-first-participant/?sc=rsin Mon, 14 Mar 2022 09:00:04 EST The first 12 study participants have been enrolled in a new Phase 1 clinical trial using the messenger ribonucleic acid (mRNA) vaccine technology developed by Moderna. The study evaluates the safety of and immune responses to three different experimental vaccines against HIV. This randomized, open-label trial represents one of the first clinical studies of the use of mRNA vaccine technology against HIV. HIV Vaccine Trials Network /articles/hvtn-faith-initiative-expands-to-help-build-bridges-between-community-and-hiv-vaccine-trials/?sc=rsin /articles/hvtn-faith-initiative-expands-to-help-build-bridges-between-community-and-hiv-vaccine-trials/?sc=rsin Tue, 14 Dec 2021 20:05:11 EST While the rapid development of effective vaccines has helped combat the COVID-19 pandemic, key communities - especially people who are living with HIV - remain disproportionately impacted, and are at higher risk of severe disease and death. Finding an effective HIV vaccine is critically important, and to that end, the HIV Vaccine Trials Network (HVTN) is launching an expanded Faith Initiative that will help advance the work of finding a cure. HIV Vaccine Trials Network /articles/antibody-mediated-prevention-amp-trials-data-published-by-the-new-england-journal-of-medicine/?sc=rsin /articles/antibody-mediated-prevention-amp-trials-data-published-by-the-new-england-journal-of-medicine/?sc=rsin Thu, 18 Mar 2021 09:00:26 EST The proof-of-concept AMP studies demonstrated that a broadly neutralizing antibody (bnAb) called VRC01 was effective at preventing the acquisition of HIV strains to the 30% of strains that were sensitive to the bnAb. This finding was seen both in Sub-Saharan Africa and the U.S. and South America. VRCO1 did not prevent the acquisition of HIV to strains that were resistant to the bNAb. HIV Vaccine Trials Network